Entera Bio Ltd. Capital expenditures

Capital expenditures of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.

Highlights and Quick Summary

  • Capital expenditures for the quarter ending June 29, 2020 was $0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Capital expenditures decreased by -100.0%
  • Annual Capital expenditures for 2019 was $-40 Thousand (a -41.18% decrease from previous year)
  • Annual Capital expenditures for 2018 was $-68 Thousand (a 33.33% increase from previous year)
  • Twelve month Capital expenditures ending June 29, 2020 was $-32 Thousand (a -11.11% decrease compared to previous quarter)
  • Twelve month trailing Capital expenditures decreased by -20.0% year-over-year
Trailing Capital expenditures for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-32 Thousand $-36 Thousand $-40 Thousand $-40 Thousand
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital expenditures of Entera Bio Ltd.

Most recent Capital expendituresof ENTX including historical data for past 10 years.

Interactive Chart of Capital expenditures of Entera Bio Ltd.

Entera Bio Ltd. Capital expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.0 $-0.03
2019 $0.0 $-0.0 $-0.0 $-0.03 $-0.04
2018 $0.0 $0.0 $-0.02 $-0.05 $-0.07
2017 $-0.05 $-0.05

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.